In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
In August CTS begins source plasma testing as a new line of business to one of the largest plasma fr...
In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...
By the end of 2017, CTS has secured three source plasma partners and continues to seek additional pa...
Transitioned all 6 CTS labs from an investigational new drug (IND) to a licensed Zika test, and anno...
Continue to meet or exceed healthcare partners’ expectations by providing on-time test results appr...
CTS embraces a company-wide operational excellence initiative designed to change the culture to enha...